We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
miiCARE is a MedTech specialising in AI applied to geriatrics (elderly care). Its key product miiCUBE offers cutting-edge home-based and customised healthcare, helping the elderly enjoy their independence while being comprehensively connected to their families, friends, and neighbours. The company aims to provide these benefits to one billion people by 2028, comprising older people, family members and carers. Till date, miiCARE has secured partnerships with the UK’s largest NHS trust, Ebbsfleet Garden City, O2, Bristol Careline and Microsoft, and won multiple social impacts and digital health awards during the last 12 months. Funds raised will be used mainly for fulfilling pre-orders and close interests for large contracts with corporates, marketing and logistics, product development, sales and salaries.

Pitch Rated

84%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £103,672
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.

Pitch Rated

82%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £70,900
ePOS Hybrid has developed a fully connected ePOS platform dedicated to the hospitality food industry. The company is on a mission to empower hospitality businesses to harness technology to improve the business operations, customer experience and profitability. Till now, they have secured an enterprise customer with locations throughout the UK and, in just 8 months, scaled from 0 to 200 customers, processing more than 400k orders. With the proceeds, the company plans to accelerate growth by increasing its market awareness and boosting sales.

Pitch Rated

82%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £363,830
Doodle Drinks (DD) aims to make all-natural soft drinks that kids can enjoy. The company cites research data arguing that children aged 18 months to 18 years are drinking 26% fewer sugary drinks and consumption for 10-year olds has fallen 35%. It wants to capture this sentiment and deliver a soft drink that's a healthy choice for both parents and their kids. DD has secured distribution with the noted distributor, Bravura Foods. It has also signed a partnership with the largest independent bottler of beverages in Europe and North America, Refresco, who have over 60 manufacturing sites globally to fulfil its objective. DD will use the investment to grow its business, execute its marketing strategy and increase its product range.

Pitch Rated

80%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £877,830
Alyve provides personalised subscription nutrition powered by Artificial Intelligence (AI). It argues that 8.2 million UK vitamin users are looking for personalised nutrition in one capsule. Alyve asserts that its product can fulfil this demand. Users complete a 3-minute questionnaire where their responses are recorded by Alyve's intelligent algorithms. These then, based on the responses, help the user select one of Alyve's nutritional pills best matched to their goals and needs. Alyve then delivers the pills to the user's doorstep every 30 days. The company has recorded 4000+ questionnaires and completed 800+ orders in 25 countries since Q4 of 2020. It aims to become a contender in the $21 billion supplement market. The company will use the investment received to increase marketing efforts, transform Alyve into a household brand, introduce new product lines, increase staff, improve technology, and transform both digital and physical User Experiences (UX).

Pitch Rated

80%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £227,782
Medics2You's is a hybrid telehealth platform that connects patients with healthcare experts around the globe with focus on Africa through a smart device from anywhere, six days a week. The company has a pilot project underway in Nigeria, a nation which spends $500m-1bn annually on outbound healthcare tourism. Medics2You aims to reach out to over 100m people unable to access quality healthcare. Medics2You's partnership with Lantum has given the company access to 18000+ doctors and 3000 clinicians. The funds will be used to create the web portal, expand the team, set up local centres, and enhance marketing activities.

Pitch Rated

76%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £156,370
Drop Drinks creates vintage beverages with a distinctive taste. Theses beverages are inspired by traditional British sweets like Pear Drop and Cherry Drop. The company has sold more than 10,000 units since its launch in 2018. With more than 9,000 followers on social platforms such as Facebook and Instagram, Drop Drinks aims at increasing its product range to become a popular and leading drink brand domestically and grow globally. The company is now raising funds to increase production, execute an extensive go-to-market strategy, and hire key staff.

Pitch Rated

71%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £127,690
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph